• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Xencor Inc.

    11/12/24 4:01:23 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XNCR alert in real time by email
    SC 13G/A 1 xncra16_111124.htm PRIMECAP MANAGEMENT CO/CA/ xncra16_111124.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 16)*
    Xencor, Inc.
    (Name of Issuer)
    COM
    (Title of Class of Securities)
    98401F105
    (CUSIP Number)
    September 30, 2024
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 98401F105
           
    1
    NAME OF REPORTING PERSON
    PRIMECAP Management Company
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    95-3868081
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    9,137,195
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    9,137,195
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    9,137,195
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    13.08%
    12
    TYPE OF REPORTING PERSON
    IA
    CUSIP No.: 98401F105
    ITEM 1(a). NAME OF ISSUER:
    Xencor, Inc.
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    465 North Halstead Street, Suite 200, Pasadena, CA 91107
    ITEM 2(a). NAME OF PERSON FILING:
    PRIMECAP Management Company
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105
    ITEM 2(c). CITIZENSHIP:
    U.S.A.
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    COM
    ITEM 2(e). CUSIP NUMBER:
    98401F105
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    9,137,195
    (b) Percent of class:
    13.08%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    PRIMECAP Management Company : 9,137,195
    (ii) shared power to vote or to direct the vote:
    PRIMECAP Management Company : 0
    (iii) sole power to dispose or direct the disposition of:
    PRIMECAP Management Company : 9,137,195
    (iv) shared power to dispose or to direct the disposition of:
    PRIMECAP Management Company : 0
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    Various Persons have the right to receive, or the power to direct the receipt of, dividends from, or proceeds from the sale of, with respect to the securities as to which this Schedule is filed. No one Person here has an interest more than five percent of this class of securities except as follows: PRIMECAP Odyssey Aggressive Growth Fund has an interest of more than five percent of the total outstanding common stock of Xencor, Inc.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Not Applicable
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    Not Applicable
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    Not Applicable
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 98401F105
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    November 11 2024
    PRIMECAP Management Company
    By:
    /s/ Jorge A. Rodriguez
    Name:
    Jorge A. Rodriguez
    Title:
    Deputy Chief Compliance Officer
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    Get the next $XNCR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XNCR

    DatePrice TargetRatingAnalyst
    9/17/2025$6.00Underweight
    Barclays
    9/3/2025$12.00Buy → Neutral
    BofA Securities
    4/21/2025Outperform
    William Blair
    12/12/2024$37.00Overweight
    Wells Fargo
    12/2/2024$20.00 → $30.00Neutral → Overweight
    Piper Sandler
    4/16/2024$56.00 → $38.00Buy
    BTIG Research
    2/28/2024$37.00 → $24.00Overweight → Neutral
    Piper Sandler
    5/19/2023$42.00Buy
    BofA Securities
    More analyst ratings

    $XNCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Gorman Kevin Charles bought $1,013 worth of shares (53 units at $19.12), increasing direct ownership by 1% to 5,060 units (SEC Form 4)

    4 - Xencor Inc (0001326732) (Issuer)

    2/15/24 4:02:46 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    SEC Filings

    View All

    Xencor Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Xencor Inc (0001326732) (Filer)

    10/24/25 1:57:11 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Xencor Inc.

    SCHEDULE 13G - Xencor Inc (0001326732) (Subject)

    10/17/25 4:56:24 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Xencor Inc.

    SCHEDULE 13G/A - Xencor Inc (0001326732) (Subject)

    8/14/25 1:29:35 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Xencor with a new price target

    Barclays resumed coverage of Xencor with a rating of Underweight and set a new price target of $6.00

    9/17/25 8:04:06 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor downgraded by BofA Securities with a new price target

    BofA Securities downgraded Xencor from Buy to Neutral and set a new price target of $12.00

    9/3/25 8:04:26 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Xencor

    William Blair initiated coverage of Xencor with a rating of Outperform

    4/21/25 8:40:03 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

    -- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose range -- -- First dose-expansion cohort has been selected; dose escalation continues to identify dose for second expansion cohort -- -- Management hosting webcast and conference call today at 1:30 p.m. ET / 10:30 a.m. PT -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with a

    10/24/25 12:30:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24 at 1:30 p.m. ET (10:30 a.m. PT) to discuss initial results from the ongoing Phase 1 dose-escalation study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma. The live webcast of the conference call may be accessed through this link and through "Events & Presentations" in the Investors section of the Company's website, located at investors.xencor.com. A recording will be available for at l

    10/21/25 8:01:00 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell

    10/17/25 9:50:00 AM ET
    $EDAP
    $EVAX
    $GTBP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    $XNCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Deshaies Raymond Joseph

    4 - Xencor Inc (0001326732) (Issuer)

    7/31/25 7:02:34 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Deshaies Raymond Joseph

    3 - Xencor Inc (0001326732) (Issuer)

    7/31/25 7:01:03 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Montgomery Alan Bruce was granted 13,686 shares and sold $20,422 worth of shares (2,215 units at $9.22), increasing direct ownership by 126% to 20,611 units (SEC Form 4)

    4 - Xencor Inc (0001326732) (Issuer)

    6/16/25 7:35:14 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Leadership Updates

    Live Leadership Updates

    View All

    Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies is a pioneering biochemist and cell biologist with more than 25 years of experience in biotechnology and drug development. He recently served as senior vice president of global research at Amgen Inc., where he oversaw all research activities, including the nomination of over 50 clinical candidates, expansion of Amgen's capabilities for discovering and optimizing multispecific drug candidates, and application of generative protein desig

    7/31/25 4:01:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor Appoints Todd Simpson to Board of Directors

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies and in public accounting. Most recently he served as CFO at Seagen Inc. through its acquisition in 2023. "Mr. Simpson is an accomplished finance and operations executive with broad experience in corporate strategy, and he played a key role in transforming a small development-stage biotech company into one of the most successful growth c

    3/13/25 4:01:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor Appoints Bart Cornelissen as Chief Financial Officer

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at Seagen Inc., where he was instrumental in the company's transformation into a global, multi-product organization that generated over $2 billion in annual revenue. "Bart's exceptional track record in financial planning and analysis

    4/9/24 8:01:00 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Xencor Inc.

    SC 13G/A - Xencor Inc (0001326732) (Subject)

    11/14/24 6:16:13 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xencor Inc.

    SC 13G/A - Xencor Inc (0001326732) (Subject)

    11/14/24 1:22:36 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xencor Inc.

    SC 13G/A - Xencor Inc (0001326732) (Subject)

    11/12/24 4:01:23 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XNCR
    Financials

    Live finance-specific insights

    View All

    Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

    -- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose range -- -- First dose-expansion cohort has been selected; dose escalation continues to identify dose for second expansion cohort -- -- Management hosting webcast and conference call today at 1:30 p.m. ET / 10:30 a.m. PT -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial results from the ongoing Phase 1 dose-escalation study of XmAb819, a ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with a

    10/24/25 12:30:00 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24 at 1:30 p.m. ET (10:30 a.m. PT) to discuss initial results from the ongoing Phase 1 dose-escalation study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma. The live webcast of the conference call may be accessed through this link and through "Events & Presentations" in the Investors section of the Company's website, located at investors.xencor.com. A recording will be available for at l

    10/21/25 8:01:00 AM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell

    10/17/25 9:50:00 AM ET
    $EDAP
    $EVAX
    $GTBP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations